In this episode of CEO Roadshow, we’re joined by Mr. Thomas Equels, CEO of Hemispherx Biopharma, an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology.
They trade on the under ticker HEB.
In this interview, Mr. Equels discusses the ongoing clinical trials the company is currently conducting with their pipeline candidate, Ampligen.
Please see the following press release regarding the collaboration with Roswell Park Cancer Center and Keytruda.
Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center
[ Ссылка ]
The Phase II Study Will Combine Hemispherx’s Ampligen with Keytruda
Hemispherx is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
The new management team has achieved several recent milestones including:
1. The first shipment of Ampligen delivered for sale in Europe utilizing the Early Access Program (EAP)
2. EAP in Europe extended to pancreatic cancer patients beginning in the Netherlands
3. FDA approval to increase price for US-based Ampligen cost recovery program
4. Initiated a commercial scale production plan with our primary contract manufacturer to meet anticipated future demands in both international programs as well as domestic programs
5. Collaboration with Millions Missing Canada to bring medication to Canadians for ME/CFS
6. Completed an intranasal human safety study of Ampligen plus FluMist® and has commenced full data analysis
7. Top-line results show intranasal Ampligen was generally well-tolerated
8. Continuing discussions with FDA to identify a path toward approval for ME/CFS
9. Cut Burn rate by over 50% and still reached milestones
Forward-Looking Statements
This CEOROADSHOW.COM video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.
Contact CEOROADSHOW.COM
Mike Elliott
me@CEOROADSHOW.COM
Disclaimer
Neither CEOROADSHOW.COM or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, CEOROADSHOW.COM/disclaimer.
CEOROADSHOW content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOROADSHOW content and productions, or other investor relations materials and presentations are subject to change. Neither CEOROADSHOW nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information are provided for informational or entertainment purposes only. CEOROADSHOW is not a registered broker-dealer or a registered investment advisor.
